Media Articles Related to Rilutek (Riluzole)
First oral liquid form of riluzole, Teglutik®, launched in the UK providing an important new treatment option for patients with ALS
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.12.18]
Martindale Pharma today announced the launch of Teglutik®, a unique oral liquid-suspension formulation of riluzole, the only licensed drug for patients with amyotrophic lateral sclerosis (ALS)...
New therapy halts progression of Lou Gehrig's disease in mice
Source: Muscular Dystrophy / ALS News From Medical News Today [2016.01.29]
Researchers at Oregon State University have announced that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for nearly two years in one...
Research discovers potential new therapeutic target for ALS
Source: Muscular Dystrophy / ALS News From Medical News Today [2016.01.20]
J. Gavin Daigle, a PhD candidate at the LSU Health New Orleans School of Graduate Studies, is the first author of a paper whose findings reveal another piece of the Amyotrophic Lateral Sclerosis...
ALS: Treeway announces positive data from two separate Phase I TW001 clinical trials
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.12.11]
Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announces the completion of two successful phase I trials with their lead compound TW001, a new...
Virginia Tech Carilion Research Institute scientists unexpectedly find ALS affects sensory neurons involved in movement
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.11.24]
The same nerves that keep a person from crushing a flower or dropping a water glass are teaching scientists something new about amyotrophic lateral sclerosis.
Published Studies Related to Rilutek (Riluzole)
12-week, placebo-controlled trial of add-on riluzole in the treatment of
childhood-onset obsessive-compulsive disorder. 
Many children with childhood-onset obsessive-compulsive disorder (OCD) fail to
respond adequately to standard therapies... However, future studies may show benefits for less
treatment-refractory children with fewer concomitant medications.
Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury. [2011.06]
The objectives of this study were to probe the contribution of spinal neuron persistent sodium conductances to reflex hyperexcitability in human chronic spinal cord injury... These results suggest that intrinsic spinal cellular excitability could be a target for managing chronic spinal cord injury hyperreflexia impairments without causing a significant loss in volitional strength.
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. [2010.05]
BACKGROUND: In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS). We aimed to confirm or disprove these findings by assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS... INTERPRETATION: We found no evidence that lithium in combination with riluzole slows progression of ALS more than riluzole alone. The time-to-event endpoint and use of prespecified interim analyses enabled a clear result to be obtained rapidly. This design should be considered for future trials testing the therapeutic efficacy of drugs that are easily accessible to people with ALS. FUNDING: National Institute of Neurological Disorders and Stroke, ALS Association, and ALS Society of Canada. Copyright 2010 Elsevier Ltd. All rights reserved.
Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. [2010.03.09]
BACKGROUND: The pleiotropic effects of riluzole may antagonize common mechanisms underlying chronic cerebellar ataxia, a debilitating and untreatable consequence of various diseases... CONCLUSIONS: These findings indicate the potential effectiveness of riluzole as symptomatic therapy in diverse forms of cerebellar ataxia. Classification of evidence: This study provides Class I evidence that riluzole reduces, by at least 5 points, the ICARS score in patients with a wide range of disorders that cause cerebellar ataxia (risk difference 63.2%, 95% CI 33.5%-79.9%).
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. [2010.02]
The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit transient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD) aimed to (1) replicate the acute efficacy of single-dose intravenous (i.v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse; and (3) examine whether pretreatment with lamotrigine would attenuate ketamine's psychotomimetic effects and enhance its antidepressant activity.
Clinical Trials Related to Rilutek (Riluzole)
Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD) [Recruiting]
The purpose of this study is to determine whether Riluzole is effective in the augmentation
treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty
military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom
(OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or
more kinds of medications or therapies.
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression [Active, not recruiting]
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Recruiting]
This phase I trial studies the side effects and best dose of sorafenib tosylate when given
together with riluzole in treating patients with advanced solid tumors or melanoma. Riluzole
may stop or slow the growth of tumor cells. Sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving riluzole together with
sorafenib tosylate may kill more tumor cells.
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders [Completed]
This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive
Disorder in Youth, Including those with Autism Spectrum Disorders.
Riluzole Augmentation Pilot in Depression (RAPID) Trial [Recruiting]
The investigators are doing a research study to find out if riluzole, when taken along with
a standard antidepressant (sertraline) can help people with major depression.
This research study will compare riluzole + sertraline to placebo + sertraline. The
investigators hypothesize that adding riluzole will lead to a better antidepressant
response, in less time, then sertraline alone.
Reports of Suspected Rilutek (Riluzole) Side Effects
Respiratory Failure (3),
Confusional State (2),
Pulse Abnormal (2),
OFF Label USE (2),
Weight Increased (2), more >>